<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016327</url>
  </required_header>
  <id_info>
    <org_study_id>CDCA-354-001</org_study_id>
    <nct_id>NCT01016327</nct_id>
  </id_info>
  <brief_title>Study of NMS-1116354 in Solid Tumors</brief_title>
  <official_title>A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerviano Medical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerviano Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase
      inhibitor, in adult patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinuation of clinical investigation with NMS-1116354
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MTD)</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics: plasma concentration at different times after dosing, area under the curve (AUC), maximum plasma concentration (Cmax), time of occurence of Cmax (tmax) and half-life (tÂ½)</measure>
    <time_frame>Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NMS-1116354</intervention_name>
    <description>Oral daily administration for 7 consecutive days every 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced/metastatic solid tumors, for which no alternative effective standard therapy
             is available

          2. Maximum of 4 regimens of prior cancer therapy allowed

          3. Prior radiotherapy allowed if no more than 25% of BM reserve irradiated

          4. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer
             therapy

          5. ECOG performance status (PS) 0 or 1

          6. Adult (age &gt;/= 18 and &lt;/= 80 years) patients

          7. Adequate renal, liver and BM reserve

          8. Capability to swallow capsules intact

        Exclusion Criteria:

          1. Current enrollment in another therapeutic clinical trial

          2. Known brain metastases

          3. Currently active second malignancy

          4. Major surgery within 4 weeks prior to treatment

          5. Any of the following in the past 6 months: myocardial infarction, unstable angina,
             coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
             cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein
             thrombosis

          6. Pregnancy or breast-feeding women

          7. Known active infections

          8. Gastrointestinal disease or other malabsorption syndromes that would impact on drug
             absorption

          9. Adrenal insufficiency

         10. Other severe acute or chronic medical or psychiatric condition that could compromise
             protocol objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Papadopoulos, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Accelerated Research Therapeutics (START)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Laffranchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nerviano Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefania Crippa, Biotech D, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nerviano Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I study</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Cdc7 kinase inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

